Zhang Fan, Lu Yi-Ping
Department of Urology, West China Hospital of Sichuan University, Chendu, Sichuan 610041, China.
Zhonghua Nan Ke Xue. 2020 Apr;26(4):364-368.
Prostate cancer (PCa) is one of the most common tumors in male. Castration-resistant PCa (CRPC) refers to the prostate malignancy with a PSA increase or imaging progression after androgen-deprivation therapy (ADT), which is divided into metastatic CRPC (mCRPC) and non-metastatic CRPC (nmCRPC) based on the presence or absence of imaging metastasis. Two second-generation antiandrogens, enzuramide and abiraterone, were approved for the treatment of nmCRPC in 2018. A recently completed three-stage large-scale clinical ARAMIS trial shows that the new drug, darolutamide, compared with the placebo, could prolong the metastasis-free survival (MFS) of nmCRPC patients. Darolutamide is now an anti-androgen drug available for patients with nmCRPC. This review focuses on the clinical trial of darolutamide and comparison of its therapeutic effect with that of another two second-generation antiandrogens.
前列腺癌（PCa）是男性最常见的肿瘤之一。去势抵抗性前列腺癌（CRPC）是指在雄激素剥夺治疗（ADT）后前列腺特异性抗原（PSA）升高或影像学进展的前列腺恶性肿瘤，根据有无影像学转移分为转移性CRPC（mCRPC）和非转移性CRPC（nmCRPC）。两种第二代抗雄激素药物，恩杂鲁胺和阿比特龙，于2018年被批准用于治疗nmCRPC。最近完成的一项三期大型临床ARAMIS试验表明，新药达罗他胺与安慰剂相比，可延长nmCRPC患者的无转移生存期（MFS）。达罗他胺现在是一种可供nmCRPC患者使用的抗雄激素药物。本综述重点关注达罗他胺的临床试验及其与另外两种第二代抗雄激素药物治疗效果的比较。
